



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 20, 2025

Curran Simpson
Chief Executive Officer
REGENXBIO Inc.
9804 Medical Center Drive
Rockville, MD 20850

Re: REGENXBIO Inc.
Registration Statement on Form S-3
Filed June 13, 2025
File No. 333-288053

Dear Curran Simpson:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Matthew C. Franker, Esq.